132 related articles for article (PubMed ID: 26574146)
21. Effect of HNF4α genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in healthy Korean individuals.
Jiang F; Yeo CW; Lee SS; Oh MK; Ghim JL; Shon JH; Kim HS; Kim EY; Kim DH; Shin JG
Pharmacogenet Genomics; 2013 Mar; 23(3):175-9. PubMed ID: 23292115
[TBL] [Abstract][Full Text] [Related]
22. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.
Wang B; Yang LP; Zhang XZ; Huang SQ; Bartlam M; Zhou SF
Drug Metab Rev; 2009; 41(4):573-643. PubMed ID: 19645588
[TBL] [Abstract][Full Text] [Related]
23. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.
Dorado P; Peñas-Lledó EM; Llerena A
Pharmacogenomics; 2007 Nov; 8(11):1597-608. PubMed ID: 18034624
[TBL] [Abstract][Full Text] [Related]
24. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse.
Corchero J; Granvil CP; Akiyama TE; Hayhurst GP; Pimprale S; Feigenbaum L; Idle JR; Gonzalez FJ
Mol Pharmacol; 2001 Dec; 60(6):1260-7. PubMed ID: 11723233
[TBL] [Abstract][Full Text] [Related]
25. High-Fat Diet Feeding Alters Expression of Hepatic Drug-Metabolizing Enzymes in Mice.
Ning M; Jeong H
Drug Metab Dispos; 2017 Jul; 45(7):707-711. PubMed ID: 28442500
[TBL] [Abstract][Full Text] [Related]
26. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles.
Bogni A; Monshouwer M; Moscone A; Hidestrand M; Ingelman-Sundberg M; Hartung T; Coecke S
Toxicol In Vitro; 2005 Aug; 19(5):621-9. PubMed ID: 15893449
[TBL] [Abstract][Full Text] [Related]
27. V79 Chinese hamster cells genetically engineered for polymorphic cytochrome P450 2D6 and their predictive value for humans.
Krebsfaenger N; Mürdter TE; Zanger UM; Eichelbaum MF; Doehmer J
ALTEX; 2003; 20(3):143-54. PubMed ID: 12947487
[TBL] [Abstract][Full Text] [Related]
28. Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate.
McConnachie L; Bodor M; Kowdley K; Levy A; Tung B; Thummel K; Phillips B; Bajpai M; Chi V; Esmay JD; Shen DD; Ho RJ
Clin Pharmacol Ther; 2004 Apr; 75(4):282-97. PubMed ID: 15060507
[TBL] [Abstract][Full Text] [Related]
29. Decreased nuclear receptor activity and epigenetic modulation associates with down-regulation of hepatic drug-metabolizing enzymes in chronic kidney disease.
Velenosi TJ; Feere DA; Sohi G; Hardy DB; Urquhart BL
FASEB J; 2014 Dec; 28(12):5388-97. PubMed ID: 25208844
[TBL] [Abstract][Full Text] [Related]
30. Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites.
Mürdter TE; Kerb R; Turpeinen M; Schroth W; Ganchev B; Böhmer GM; Igel S; Schaeffeler E; Zanger U; Brauch H; Schwab M
Hum Mol Genet; 2012 Mar; 21(5):1145-54. PubMed ID: 22108178
[TBL] [Abstract][Full Text] [Related]
31. Differences in the Epigenetic Regulation of Cytochrome P450 Genes between Human Embryonic Stem Cell-Derived Hepatocytes and Primary Hepatocytes.
Park HJ; Choi YJ; Kim JW; Chun HS; Im I; Yoon S; Han YM; Song CW; Kim H
PLoS One; 2015; 10(7):e0132992. PubMed ID: 26177506
[TBL] [Abstract][Full Text] [Related]
32. Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications.
Ford KA; Ryslik G; Sodhi J; Halladay J; Diaz D; Dambach D; Masuda M
Drug Metab Rev; 2015 Aug; 47(3):291-319. PubMed ID: 26024250
[TBL] [Abstract][Full Text] [Related]
33. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
Yu A; Kneller BM; Rettie AE; Haining RL
J Pharmacol Exp Ther; 2002 Dec; 303(3):1291-300. PubMed ID: 12438554
[TBL] [Abstract][Full Text] [Related]
34. Negative autoregulation of HNF-4alpha gene expression by HNF-4alpha1.
Magenheim J; Hertz R; Berman I; Nousbeck J; Bar-Tana J
Biochem J; 2005 May; 388(Pt 1):325-32. PubMed ID: 15651981
[TBL] [Abstract][Full Text] [Related]
35. Complexities of CYP2D6 gene analysis and interpretation.
Gaedigk A
Int Rev Psychiatry; 2013 Oct; 25(5):534-53. PubMed ID: 24151800
[TBL] [Abstract][Full Text] [Related]
36. The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha.
Saborowski M; Kullak-Ublick GA; Eloranta JJ
J Pharmacol Exp Ther; 2006 May; 317(2):778-85. PubMed ID: 16436500
[TBL] [Abstract][Full Text] [Related]
37. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.
Brockmöller J; Kirchheiner J; Schmider J; Walter S; Sachse C; Müller-Oerlinghausen B; Roots I
Clin Pharmacol Ther; 2002 Oct; 72(4):438-52. PubMed ID: 12386646
[TBL] [Abstract][Full Text] [Related]
38. Nrf2 Regulates the Expression of
Siswanto FM; Handayani MDN; Firmasyah RD; Oguro A; Imaoka S
Curr Drug Metab; 2023; 24(9):667-681. PubMed ID: 37916628
[TBL] [Abstract][Full Text] [Related]
39. Physiological Regulation of Drug Metabolism and Transport: Pregnancy, Microbiome, Inflammation, Infection, and Fasting.
Morgan ET; Dempsey JL; Mimche SM; Lamb TJ; Kulkarni S; Cui JY; Jeong H; Slitt AL
Drug Metab Dispos; 2018 May; 46(5):503-513. PubMed ID: 29514828
[TBL] [Abstract][Full Text] [Related]
40. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
